UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 792

Sortiert nach

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs

JAMA : the journal of the American Medical Association, 2015-12, Vol.314 (23), p.2503

2015

Volltextzugriff (PDF)

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions

Value in health, 2017-02, Vol.20 (2), p.234-239

2017

Volltextzugriff (PDF)

Cost, Coverage, and Comparative Effectiveness Research: The Critical Issues for Oncology

Journal of clinical oncology, 2012-12, Vol.30 (34), p.4275-4281

Pearson, Steven D

2012

Volltextzugriff (PDF)

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

Annals of allergy, asthma, & immunology, 2017-02, Vol.118 (2), p.220-225

2017

Volltextzugriff (PDF)

White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market

Journal of comparative effectiveness research, 2023-10, Vol.12 (10), p.e230128-e230128

2023

Volltextzugriff (PDF)

Bedside estimates of dead space using end-tidal CO2 are independently associated with mortality in ARDS

Critical care (London, England), 2021-09, Vol.25 (1), p.1-333, Article 333

2021

Volltextzugriff (PDF)

Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

Nature communications, 2022-11, Vol.13 (1), p.6615-6615, Article 6615

2022

Volltextzugriff (PDF)

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value

Value in health, 2018-03, Vol.21 (3), p.258-265

Pearson, Steven D.

2018

Volltextzugriff (PDF)

Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies

Journal of comparative effectiveness research, 2023-12, Vol.12 (12), p.e230154-e230154

2023

Volltextzugriff (PDF)

The Patient Not in the Room

Annals of internal medicine, 2021-01, Vol.174 (1), p.109

Pearson, Steven D

2021

Volltextzugriff (PDF)

Patients' Trust in Physicians: Many Theories, Few Measures, and Little Data

Journal of general internal medicine : JGIM, 2000-07, Vol.15 (7), p.509-513

2000

Volltextzugriff (PDF)

Indication-specific pricing of pharmaceuticals in the US healthcare system

Journal of comparative effectiveness research, 2017-07, Vol.6 (5), p.397-404

2017

Volltextzugriff (PDF)

Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer

Journal of clinical oncology, 2012-02, Vol.30 (6), p.661-666

2012

Volltextzugriff (PDF)

Why the Coming Debate Over the QALY and Disability Will be Different

The Journal of law, medicine & ethics, 2019-06, Vol.47 (2), p.304-307

Pearson, Steven D.

2019

Volltextzugriff (PDF)

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

JAMA : the journal of the American Medical Association, 2016-08, Vol.316 (7), p.743

2016

Volltextzugriff (PDF)

Value assessment and heterogeneity: another side to the story

The American journal of managed care, 2019-11, Vol.25 (11), p.542-543

Pearson, Steven D

2019

Volltextzugriff (PDF)

Novel Therapies for an Aging Population: Grappling With Price, Value, and Affordability

JAMA : the journal of the American Medical Association, 2019-04, Vol.321 (16), p.1567

2019

Volltextzugriff (PDF)

Evolving targets for sedation during mechanical ventilation

Current opinion in critical care, 2020-02, Vol.26 (1), p.47

2020

Volltextzugriff (PDF)

An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year

PharmacoEconomics, 2023-10, Vol.41 (10), p.1175-1182

2023

Volltextzugriff (PDF)

The next generation of rare disease drug policy: ensuring both innovation and affordability

Journal of comparative effectiveness research, 2022-10, Vol.11 (14), p.999-1010

2022

Volltextzugriff (PDF)

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

Value in health, 2018-05, Vol.21 (5), p.547-552

2018

Volltextzugriff (PDF)

Evidentiary rationales for the Choosing Wisely Top 5 lists

JAMA : the journal of the American Medical Association, 2014-04, Vol.311 (14), p.1443

2014

Volltextzugriff (PDF)

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19

Value in health, 2022-05, Vol.25 (5), p.744-750

2022

Volltextzugriff (PDF)

Noninvasive Ventilation for Acute Asthma: The Neglected Sibling

American journal of respiratory and critical care medicine, 2020-12, Vol.202 (11), p.1491-1493

2020

Volltextzugriff (PDF)

How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study

Value in health, 2024-08, Vol.27 (8), p.1066-1072

2024

Volltextzugriff (PDF)

1 – 25 von 792

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(583)
Mit Volltextzugriff
(614)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions

Cost, Coverage, and Comparative Effectiveness Research: The Critical Issues for Oncology

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market

Bedside estimates of dead space using end-tidal CO2 are independently associated with mortality in ARDS

Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value

Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies

The Patient Not in the Room

Patients' Trust in Physicians: Many Theories, Few Measures, and Little Data

Indication-specific pricing of pharmaceuticals in the US healthcare system

Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer

Why the Coming Debate Over the QALY and Disability Will be Different

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Value assessment and heterogeneity: another side to the story

Novel Therapies for an Aging Population: Grappling With Price, Value, and Affordability

Evolving targets for sedation during mechanical ventilation

An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year

The next generation of rare disease drug policy: ensuring both innovation and affordability

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

Evidentiary rationales for the Choosing Wisely Top 5 lists

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19

Noninvasive Ventilation for Acute Asthma: The Neglected Sibling

How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study

Suchergebnisse filtern